Abraham Getu, Kottke Claudia, Dhein Stefan, Ungemach Fritz Rupert
Faculty of Veterinary Medicine, Institute of Pharmacology, Pharmacy and Toxicology, Leipzig University, An den Tierkliniken 15, 04103 Leipzig, Germany.
Biochem Pharmacol. 2003 Sep 15;66(6):1067-81. doi: 10.1016/s0006-2952(03)00460-x.
Although in the respiratory system there is great therapeutic interest in manipulating and understanding the beta-adrenoceptor-G-protein-adenylate cyclase (AC) signal transduction pathway, little is known on segmental differences among lung, bronchus, and trachea with regard to the receptor concentration and interaction to G-proteins and coupling to AC. In this study, patterns of distribution and absolute quantities of beta-adrenoceptor subtypes beta(1) and beta(2) were determined in membranes of equine lung parenchyma, bronchial and tracheal epithelium with the underlying smooth muscle by saturation and competition binding assays using the radioligand (-)-[125I]-iodocyanopindolol (ICYP). Additionally, the functional coupling of beta-adrenoceptors to G-proteins (assessed by beta-agonist competition binding in the presence and absence of GTP) as well as the coupling efficiency and biochemical activities of AC was investigated in each region. The specific ICYP binding was rapid, reversible, saturable with time and of high affinity. The radioligand binding identified more total beta-adrenoceptors in the lung than in bronchus or trachea (428+/-19, 162.4+/-4.8, 75.6+/-1.2 fmol/mg protein, respectively) with about 40% of receptors in the high affinity state. The beta(2)-adrenoceptor subtype predominated in all segments (approximately 74-80%), as the highly selective beta(2)-adrenoceptor antagonist ICI 118,551 was about 10,000 times more potent in inhibiting ICYP binding than was the beta(1)-selective adrenoceptor antagonist CGP 20712A, and beta-adrenoceptor agonists inhibited ICYP binding with an order of potency: (-)-isoprenaline>(-)-adrenaline>(-)-noradrenaline. The dissociation constant (K(d)) was higher in the trachea than in bronchus or lung (13.0+/-0.9 pM vs. 20.0+/-2.3 pM vs. 30.8+/-4.4 pM, P<0.05, respectively). The beta(2)-adrenoceptor-mediated AC response was tissue-dependent; stimulants acting on beta-adrenoceptor (isoproterenol), G-protein (GTP, NaF) and AC (forskolin, Mn(2+)) enhanced AC responses in all three regions, but the AC activity was higher in tracheal crude membranes than in bronchus or lung (trachea>>>bronchus>lung), hence, the number of beta(2)-adrenoceptors correlated inversely with the amount of AC. We conclude that (1) the stoichiometry of components within the pulmonary beta-adrenoceptor-G-protein complex is segment-dependent, and (2) the receptor number or AC activity is possibly the rate-limiting factor in the beta-adrenoceptor-G-protein-AC-mediated physiological responses. Thus, it is speculated that this could have important therapeutic consequences in beta-adrenoceptor agonist-induced receptor regulation in bronchial asthma.
尽管在呼吸系统中,操纵和理解β-肾上腺素能受体-G蛋白-腺苷酸环化酶(AC)信号转导途径具有极大的治疗意义,但关于肺、支气管和气管在受体浓度、与G蛋白的相互作用以及与AC的偶联方面的节段性差异,我们所知甚少。在本研究中,通过使用放射性配体(-)-[125I]-碘氰吲哚洛尔(ICYP)的饱和与竞争结合试验,测定了马肺实质、支气管和气管上皮及其下层平滑肌膜中β-肾上腺素能受体亚型β(1)和β(2)的分布模式和绝对数量。此外,还研究了每个区域中β-肾上腺素能受体与G蛋白的功能偶联(通过在有和没有GTP的情况下β-激动剂竞争结合来评估)以及AC的偶联效率和生化活性。特异性ICYP结合快速、可逆、随时间饱和且具有高亲和力。放射性配体结合显示,肺中总的β-肾上腺素能受体比支气管或气管中的更多(分别为428±19、162.4±4.8、75.6±1.2 fmol/mg蛋白),约40%的受体处于高亲和力状态。β(2)-肾上腺素能受体亚型在所有节段中占主导地位(约74-80%),因为高度选择性的β(2)-肾上腺素能受体拮抗剂ICI 118,551在抑制ICYP结合方面的效力比β(1)-选择性肾上腺素能受体拮抗剂CGP 20712A强约10,000倍,并且β-肾上腺素能受体激动剂抑制ICYP结合的效力顺序为:(-)-异丙肾上腺素>(-)-肾上腺素>(-)-去甲肾上腺素。解离常数(K(d))在气管中高于支气管或肺(分别为13.0±0.9 pM对20.0±2.3 pM对30.8±4.4 pM,P<0.05)。β(2)-肾上腺素能受体介导的AC反应具有组织依赖性;作用于β-肾上腺素能受体(异丙肾上腺素)、G蛋白(GTP、NaF)和AC(福斯高林、Mn(2+))的刺激剂在所有三个区域均增强了AC反应,但气管粗膜中的AC活性高于支气管或肺(气管>>>支气管>肺),因此,β(2)-肾上腺素能受体的数量与AC的量呈负相关。我们得出结论:(1)肺β-肾上腺素能受体-G蛋白复合物中各成分的化学计量是节段依赖性的,(2)受体数量或AC活性可能是β-肾上腺素能受体-G蛋白-AC介导的生理反应中的限速因素。因此,推测这可能对支气管哮喘中β-肾上腺素能受体激动剂诱导的受体调节具有重要的治疗意义。